Method Of Making A Transgenic Nonhuman Animal Patents (Class 800/21)
-
Publication number: 20100311817Abstract: Disclosed are rationally-designed, non-naturally-occurring meganucleases in which a pair of enzyme subunits having specificity for different recognition sequence half-sites are joined into a single polypeptide to form a functional heterodimer with a non-palindromic recognition sequence. The invention also relates to methods of producing such meganucleases, and methods of producing recombinant nucleic acids and organisms using such meganucleases.Type: ApplicationFiled: April 30, 2010Publication date: December 9, 2010Inventors: James J. Smith, Derek Jantz
-
Publication number: 20100306869Abstract: The present invention relates to methods of modulating traits, particularly production traits, in avians such as chickens. In particular, the invention relates to the in ovo delivery of a dsRNA molecule, especially siRNAs, to modify production traits in commercially important birds.Type: ApplicationFiled: June 12, 2008Publication date: December 2, 2010Applicants: COMMWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION, AUSTRALIAN POULTRY CRC PTY LTDInventors: Timothy James Doran, Robert John Moore, John William Lowenthal
-
Patent number: 7838727Abstract: This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.Type: GrantFiled: November 4, 2005Date of Patent: November 23, 2010Assignee: Advanced Cell Technology, Inc.Inventors: Robert Lanza, Young Chung, Michael D. West
-
Publication number: 20100293623Abstract: The invention concerns a method for producing non-human mammal embryos, in particular rabbit by nuclear cloning. The invention also concerns the mammals obtained and their uses.Type: ApplicationFiled: April 15, 2009Publication date: November 18, 2010Applicant: Institut National de la Recherche AgronomiqueInventors: Patrick Chesne, Pierre Adenot, Jean-Paul Renard
-
Publication number: 20100293626Abstract: The present invention relates to a method for increasing the efficiency of offspring production in producing animals belonging to the family Canidae (canines) by somatic cell nuclear transfer. More specifically, relates to a method for increasing the efficiency of production of cloned canines by a method for cloning canines comprising enucleating the oocyte of a canine to prepare an enucleated oocyte, fusing a nuclear donor cell with the enucleated oocyte to prepare a nuclear transfer embryo and transferring the nuclear transfer embryo into the oviduct of a surrogate mother, wherein the nuclear donor cell is cultured in a medium containing a specific cell cycle synchronization-inducing substance such as roscovitine in the preparation thereof.Type: ApplicationFiled: November 19, 2008Publication date: November 18, 2010Applicant: SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATIONInventors: Byeong Chun Lee, Min Kyu Kim, Goo Jang, Hyun Ju Oh, So Gun Hong, Jung Eun Park, Jung Taek Kang
-
Publication number: 20100287633Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.Type: ApplicationFiled: February 25, 2010Publication date: November 11, 2010Applicant: TRANSPOSAGEN BIOInventors: Eric Ostertag, Blair Madison
-
Publication number: 20100287638Abstract: The present invention relates to the discovery that renewable stem cell lines can be derived from tumor cells and can be cultured in vitro. Accordingly, the invention provides neural tumor stem cell lines and cells from such cell lines. Because the cell lines retain characteristics of the tumors from which they are derived, the cells can be used in screening methods for identification of potential therapeutic agents and can be used to identify genetic markers which may be predictive for development of such tumors. Finally, such cells can be used to determine an appropriate therapeutic regimen for a patient suffering from a brain tumor. Cells from a patient's brain tumor can be cultured as described herein to create a cell line, and the relative effectiveness of a therapeutic agent against the cells can be tested to determine which agent or combination of agents is most effective in treating the patient's tumor.Type: ApplicationFiled: October 1, 2008Publication date: November 11, 2010Applicants: The Hospital for Sick Children, The University Court of the University of EdinburghInventors: Peter B. Dirks, Austin Smith, Ian D.N. Clarke, Steve Pollard
-
Publication number: 20100281554Abstract: This invention relates to a method for humanising a mouse. In particular, the invention relates to a method for replacing a cluster of mouse genes with single or multiple genes from the corresponding human cluster using a combination of homologous recombination and site-specific recombination.Type: ApplicationFiled: September 12, 2008Publication date: November 4, 2010Applicant: ITI SCOTLAND LIMITEDInventor: Nico Scheer
-
Publication number: 20100281555Abstract: Disclosed herein is a method for marking bio-information into the genome of an organism, an organism marked with inherent bio-information by the method and a method for reading the bio-information. The method is characterized in that inherent bio-information encoded to a DNA sequence or RNA sequence is inserted into genome of organisms through a gene delivery system. Inherent bio-information is inserted into genome of organisms, thus avoiding loss by cell culture or artificial manipulation and being widely used even for organisms whose host-vector system is not provided. Based on these features, the method has the following advantages. First, inherent bio-informtion can be clearly obtained from the organisms themselves, rather than an additional means such as catalogs. Second, when organisms developed through desperate efforts are stolen, they can be tracked down and identified. Third, when serious problems occur by overuse or misuse of organisms, the origin thereof can be clearly determined.Type: ApplicationFiled: December 3, 2008Publication date: November 4, 2010Applicants: Chungbuk National University Industry-Academic Cooperation Foundation, Knu-Industry Cooperation FoundationInventors: Myung-Dong Kim, Hyun-Ju Eom, Eun-Hee Park, Nam-Soo Han
-
Publication number: 20100275274Abstract: The present invention relates to Glycine N-methyltransferase (GNMT) animal model and use thereof.Type: ApplicationFiled: April 28, 2009Publication date: October 28, 2010Applicant: NATIONAL YANG-MING UNIVERSITYInventors: YI-MING CHEN, CHING-PING YANG
-
Patent number: 7820877Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V?) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.Type: GrantFiled: October 14, 2005Date of Patent: October 26, 2010Assignee: Amgen Fremont Inc.Inventors: Aya Jakobovits, Raju Kucherlapati, Sue Klapholz, Michael J. Mendez, Larry Green
-
Publication number: 20100269182Abstract: The present invention relates generally to chemical-inducible system and to methods of use in transgenic animals. More specifically, the present invention relates to a chimeric transcription factor that binds to a ligand and functions in ligand-dependent manner to induce expression of genes of interest under the control of a synthetic operator-promoter sequence. The expression of genes of interest can be tightly controlled by adding or removing the ligand.Type: ApplicationFiled: July 2, 2008Publication date: October 21, 2010Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Alexander Emelyanov, Sergey Parinov, Nam-Hai Chua
-
Patent number: 7803982Abstract: The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses transgenic animals and cells that do not express functional T1R3 protein, particularly knock-out animals and cells, and transgenic animals and cells that express a non-native T1R3 protein. Experimental model systems based on these animals and cells can be used to study T1R3-mediated taste transduction and responses of the components of the T1R3 signal transduction pathway to various tastants, furthering our understanding of the molecular biology and biochemistry of taste. Such model systems would also be useful for screening for novel tastants and taste modulators, such as enhancers of desirable flavors, and blockers of undesirable flavors.Type: GrantFiled: July 15, 2004Date of Patent: September 28, 2010Assignee: The Mount Sinai School of Medicine of New York UniversityInventors: Robert Margolskee, Minqing Rong, Sami Damak
-
Publication number: 20100235926Abstract: The present invention provides a hairless transgenic nonhuman animal used in the development of a therapy for dermatitis such as human atopic dermatitis and drug discovery. Specifically, the present invention provides a transgenic nonhuman animal, into which recombinant DNA comprising a heparin-binding EGF gene and a type 2 keratin gene promoter for regulating expression of the above gene has been introduced.Type: ApplicationFiled: February 8, 2006Publication date: September 16, 2010Inventors: Hiromichi Yonekawa, Toyoyuki Takada, Hiroshi Shitara, Yoshiaki Kikkawa, Rie Ishii, Kenji Kohno
-
Publication number: 20100235929Abstract: The invention relates to compositions and methods for producing antibodies having human idiotypes in non-human animals.Type: ApplicationFiled: May 30, 2008Publication date: September 16, 2010Applicant: Buelow Research Enterprises LLCInventor: Roland Buelow
-
Patent number: 7795494Abstract: The invention provides compositions and methods for the generation of novel non-human transgenic animals which contain an alteration in a gene of interest. These transgenic animals are capable of generating antibodies, e.g., human monoclonal antibodies, specific for the product of a gene of interest that has been functionally disrupted in the transgenic animal. Furthermore, the methods and compositions of the invention are suitable for use in the treatment, diagnosis, and imaging of disease.Type: GrantFiled: March 22, 2002Date of Patent: September 14, 2010Assignee: Abbott LaboratoriesInventor: Tariq Ghayur
-
Patent number: 7795496Abstract: The present invention provides for methods of producing transgenic avians which may include delivering a heterologous nucleic acid to oviduct tissue of an avian wherein the nucleic acid enters a cell of the oviduct tissue and is expressed.Type: GrantFiled: February 13, 2009Date of Patent: September 14, 2010Assignee: Synageva BioPharma Corp.Inventors: Leandro Christmann, Markley C. Leavitt, Dawn M. Eberhardt, Timalynn M. Matthews
-
Publication number: 20100229254Abstract: The present technology relates to a method for causing cell death. The method comprises the step of genetically manipulating chromosomal DNA of a cell such as by, for example, using a recombinase system, to lose an autosome during cell division and wherein loss of the autosome results in death of the cell. The technology also relates to a method for selective ablation of proliferative cells within a population of cells.Type: ApplicationFiled: March 4, 2009Publication date: September 9, 2010Inventors: Marie KMITA, Damien Gregoire
-
Publication number: 20100218267Abstract: This invention provides methods for producing antibodies, wherein the methods comprise the step of administering an immunogen comprising both a target antigen and a background antigen to transgenic animals, into which a gene coding for the background antigen has been introduced. Since immunotolerance to the background antigens have thus been induced in the transgenic animals, the animals efficiently produce antibodies to target antigens.Type: ApplicationFiled: May 7, 2010Publication date: August 26, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsuhiko Kodama, Kou-ichi Jishage, Nobuo Kamada, Yoshiki Yamada
-
Publication number: 20100218263Abstract: A transgenic mollusk which can express a desired foreign gene, and a method for producing the same are disclosed. The mollusk is a transgenic mollusk into which a desired foreign gene (excluding a gene giving resistance to a virus) is introduced, which expresses the foreign gene. This transgenic mollusk can be produced by microinjecting into gonad of male and/or female of mollusk a recombinant vector into which a desired foreign gene to be introduced or a nucleic acid containing the foreign gene is inserted; crossing the male and female to produce individuals of first generation; and selecting therefrom (an) individual(s) which express(es) the desired gene.Type: ApplicationFiled: May 7, 2010Publication date: August 26, 2010Inventors: Keizaburo Miki, Johji Miwa, Nozomu Isowa
-
Patent number: 7781642Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.Type: GrantFiled: December 11, 2008Date of Patent: August 24, 2010Assignee: KMT Hepatech, Inc.Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
-
Publication number: 20100212040Abstract: The invention is directed to reliable and efficient detection of mRNAs as well as other RNAs in living cells and its use to identify and, if desired, separate cells based on their desired characteristics. Such methods greatly simplify and reduce the time necessary to carry out previously-known procedures, and offers new approaches as well, such as selecting cells that generate a particular protein or antisense oligonucleotide, generating cell lines that express multiple proteins, generating cell lines with knock-out of one or more protein, and others.Type: ApplicationFiled: April 30, 2010Publication date: August 19, 2010Applicant: CHROMOCELL CORPORATIONInventors: Kambiz Shekdar, Gunter Blobel
-
Publication number: 20100212039Abstract: A method of inducing male and/or female infertility in a genetically modified (GM) fish is disclosed. Also disclosed is a method of generating an infertile GM fish with a phenotype and/or genotype of interest. The method involves generation of a GM fish whose genome comprises a foreign transgene operably linked to a fish gonad-specific promoter selected from the group consisting of an ovary-specific promoter and a testis-specific promoter. The transgene comprises a suicide gene selected from the group consisting of a reductase and a photosensitizer, in which the reductase is operably linked to a reporter gene. Infertility of the GM fish is induced if the GM fish expressing the reductase is treated with an effective amount of a reductase-activated cytotoxic prodrug or if the GM fish expressing the photosensitizer is treated with light irradiation.Type: ApplicationFiled: February 12, 2010Publication date: August 19, 2010Applicant: ACADEMIA SINICAInventors: JEN-LEIH WU, SHAO-YANG HU, GUOR MOUR HER
-
Publication number: 20100205683Abstract: This invention relates to a method for stably expressing a transgene integrated into the genome of an animal cell or of an animal over a long period. Specifically, this invention provides: an approximately 2.5 kb XhoI-BamHI fragment (or XB fragment) derived from the Evx2-Hoxd13 intergenic region of the animal genome, or a homologue thereof; a DNA containing a foreign DNA wherein the DNA has been inserted between the two essentially identical XB fragments or homologues thereof; a vector, animal cell, or nonhuman mammalian animal containing said DNA; and use of the vector, animal cell, or nonhuman mammalian animal for production of a substance or therapy.Type: ApplicationFiled: November 21, 2007Publication date: August 12, 2010Inventor: Takashi Kondo
-
Publication number: 20100205684Abstract: A chicken embryonic stem cell is established, which stably has pluripotency and an ability of being differentiated into a germ cell. For evaluating on whether or not the chicken embryonic stem cell can be applied to genetic modification technique, detection is made on a protein which serves as an indicator of the ability of being differentiated into a germ cell. This provides (i) a chicken embryonic stem cell applicable to genetic modification technique and (ii) a method for evaluation of the chicken embryonic stem cell.Type: ApplicationFiled: March 26, 2008Publication date: August 12, 2010Inventors: Hiroyuki Horiuchi, Haruo Matsuda, Shuichi Furusawa, Mikiharu Nakano, Yusuke Yamashita, Masaki Nishimoto
-
Patent number: 7772459Abstract: The invention relates to the production of proteins and other substances of interest in saliva of transgenic animals, particularly in mammals that produce large quantities of saliva, particularly monogastric ruminants, and ovine, caprine and bovine mammals. Preferred embodiments of the invention relate in particular to the production of foreign and modified proteins in the transgenic saliva of these animals, including particularly human fibrinogen, human prothrombin and human thrombin, among others. The invention relates as well to methods, devices, genetic constructs and to transgenic constructs for making the proteins and other substances of interest, to novel saliva and saliva-derived compositions, novel products from the saliva, and to uses of the saliva, saliva-derived compositions and novel products.Type: GrantFiled: February 20, 2003Date of Patent: August 10, 2010Assignee: Bellweather FarmsInventor: Jeffrey P. Erickson
-
Publication number: 20100199360Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.Type: ApplicationFiled: November 28, 2005Publication date: August 5, 2010Applicants: FRANKGEN BIOTECHNOLOGIE AG., GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Patricia Ruiz
-
Publication number: 20100192235Abstract: Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic leukemia.Type: ApplicationFiled: April 12, 2010Publication date: July 29, 2010Applicant: Thomas Jefferson UniversityInventor: Carlo M. Croce
-
Publication number: 20100186103Abstract: The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.Type: ApplicationFiled: January 12, 2010Publication date: July 22, 2010Applicant: University of MassachusettsInventors: Guangping Gao, Phillip D. Zamore
-
Publication number: 20100169995Abstract: The invention provides a non-human mammal or a cell line that has a targeted gene disruption in an endogenous Iqgap2 gene. The invention also provides methods of identifying a compound as a therapeutic agent for the treatment of hepatocellular carcinoma and methods of treating or preventing hepatocellular carcinoma.Type: ApplicationFiled: December 17, 2009Publication date: July 1, 2010Applicant: The Research Foundation of State University of New YorkInventors: Valentina Schmidt, Wadie F. Bahou
-
Publication number: 20100169986Abstract: Provided herein are novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods relating thereto. Such novel nucleic acid sequences, vectors comprising such nucleic acid sequences, host cells comprising such vectors, and transgenic animals comprising such nucleic acid sequences, and related molecules and methods provide conditional overexpression of genes, such as myostatin, and transgenic animals conditionally overexpression genes, such as myostatin.Type: ApplicationFiled: March 5, 2009Publication date: July 1, 2010Inventor: Suzanne Porszasz-Reisz
-
Publication number: 20100169991Abstract: Disclosed is a biopesticide utilizing an insect belonging to the family Coccinelidae, which has excellent durability of effect, which can control a insect pest effectively, and which has little influence on an ecosystem. An insect belonging to the family Coccinelidae having abnormality in the wing formation can be produced by suppressing the expression of a vestigial gene and/or a scalloped gene in the insect.Type: ApplicationFiled: June 13, 2007Publication date: July 1, 2010Applicant: National University Corporation Nagoya UniversityInventors: Teruyuki Niimi, Toshinobu Yaginuma
-
Publication number: 20100169996Abstract: Methods to identify nucleotide sequences whose expression will enhance resistance to pathogen infection are described, as is use of such nucleotide sequences to enhance resistance with minimal side effects on development.Type: ApplicationFiled: January 18, 2008Publication date: July 1, 2010Inventors: Lionel Navarro, Oliver Voinnet
-
Publication number: 20100162423Abstract: Methods and systems are provided for managing non-beef livestock subjects in order to maximize their individual potential performance and the value of a product from the non-beef livestock subjects, and to maximize profits obtained in marketing the non-beef livestock subjects. The methods and systems draw an inference of a trait of a non-beef livestock subject by determining the nucleotide occurrence of at least one non-beef livestock SNP that is determined to be associated with the trait.Type: ApplicationFiled: October 23, 2009Publication date: June 24, 2010Applicant: Metamorphix, Inc.Inventors: Sue DeNise, David Rosenfeld, Richard Kerr, Stephen Bates, Tom Holm
-
Publication number: 20100162416Abstract: The present invention relates to a system of multi-stage stem cell carcinogenesis and a method of generating such multi-stage stem cell carcinogenesis system. Various stages of cancer stem cells can be generated from normal stem cells via mutagenesis. The system of the present invention enables monitoring changes in the ability of cells to transition from one stage of carcinogenesis to another and to identify genetic pathways and molecules that influence carcinogenesis. The present invention also enables a high-throughput and nonbiased screening for targets that preferentially affect cancer stem cells relative to non-cancer stem cells or their derivatives during stem cell carcinogenesis, thus is useful in developing anti-cancer therapeutics.Type: ApplicationFiled: September 29, 2009Publication date: June 24, 2010Applicant: StemLifeLine, Inc.Inventors: Ana Krtolica, Dusko Ilic
-
Publication number: 20100145889Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.Type: ApplicationFiled: February 15, 2010Publication date: June 10, 2010Inventors: Alan Blake, Richard Crockett, Jeffrey Essner, Perry Hackett, Aidas Nasevicius
-
Publication number: 20100146644Abstract: A transgenic non-human animal genetically modified to have a dysfunctional 26S-proteasome in some or all cells, which may exhibit phenotypic and/or neuropathological symptoms similar to those exhibited by individuals with a neurogenerative disorder.Type: ApplicationFiled: October 31, 2007Publication date: June 10, 2010Inventor: Roland John Mayer
-
Publication number: 20100146655Abstract: Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.Type: ApplicationFiled: July 16, 2009Publication date: June 10, 2010Inventors: SCOTT C. FAHRENKRUG, DANIEL F. CARLSON, ARON M. GEURTS
-
Publication number: 20100138938Abstract: The invention relates to a method of producing a multichimeric mouse comprising a functional xenogenic (human) immune system restricted to the MHC class I and/or class II molecules (HLA molecules) of the xenogenic species solely, and a functional tissue. The invention relates also th the use of the multichimeric mouse obtainable by said method, to study the immunopathogenesis of tissue-specific diseases (infectious, tumoral or auto-immune pathologies) and to their applications to design and test vaccines or immunotherapeutic agents against these pathologies.Type: ApplicationFiled: July 13, 2007Publication date: June 3, 2010Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTESInventors: Sylvie GARCIA, Eric TARTOUR
-
Publication number: 20100138947Abstract: The present invention relates to methods and compositions for the production and derivation of pluripotent stem cells from embryos or embryo-derived cells and therapeutic uses therefor. In particular, the present invention relates to a method for producing functional stem cells or stem cell-like cells comprising the steps of culturing an embryo or embryo-derived cells in the presence of a demethylation agent and isolating functional pluripotent cells.Type: ApplicationFiled: April 28, 2006Publication date: June 3, 2010Inventors: Ivan Vassiliev, Paul John Verma
-
Publication number: 20100138936Abstract: The invention relates to the use of an expression vector construction coding for the functional HLA-DPal03?401 complex specifically identified by anti-HLA-DP antibodies, in order to create transgenic mice. The invention also relates to the use of the transgenic mice obtained, such as for the comparative preclinical study of the efficacy of vaccine candidates in order to asses the risks associated with the unwanted induction of an autoimmune disease and in order to determine a therapeutic strategy.Type: ApplicationFiled: March 6, 2006Publication date: June 3, 2010Inventors: Yu-Chun Lone, Anthony Pajot, François Lemonnier
-
Publication number: 20100138946Abstract: The present invention is transgenic chickens obtained from long-term cultures of avian PGCs and techniques to produce and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. This invention includes compositions comprising long-term cultures of PGCs and offspring derived from them that are genetically modified.Type: ApplicationFiled: August 14, 2008Publication date: June 3, 2010Inventors: Marie-Cecile Van de Lavoir, Philip Albert Leighton
-
Publication number: 20100132055Abstract: The present invention relates to a non-human animal model, cell and tissue cultures derived therefrom, which do not produce or produce only suboptimal levels of one or more functional sestrins and in addition do not produce or do only produce suboptimal levels of latent transforming growth factor ? binding protein 4 (ltbp4). Furthermore, the present invention relates to a method for selecting agents for treating the pulmonary emphysema and/or the colorectal cancer exhibited by utilizing the animal model, cell or tissue culture of the invention. The animal model, cell or tissue culture is suitable for preclinical testing of efficacy, toxicity and bioavailability of potential agents.Type: ApplicationFiled: September 4, 2007Publication date: May 27, 2010Applicant: FRANKGEN BIOTECHNOLOGIE AGInventors: Harald von Melchner, Frank Wempe, Silke De-Zolt
-
Patent number: 7718846Abstract: Provided are animal models of long QT syndrome (LQTS). The animal models are useful, for example, in screening of drugs for adverse effects in subjects with LQTS, in screening candidate therapeutics for the treatment or prevention of LQTS, and in determining gene expression in LQTS.Type: GrantFiled: May 16, 2005Date of Patent: May 18, 2010Inventors: Gideon Koren, Xuwen Peng, Rajesh Mathur, Manfred Zahender
-
Patent number: 7718847Abstract: The present invention provides a method of producing a non-human vertebrate that harbours germ cells having a desired gene transferred thereto, comprising injecting the desired gene to the testis of a non-human vertebrate wherein no tight junction exists between Sertoli cells to transfer the desired gene to germ cells, so as to obtain a non-human vertebrate that harbours the germ cells having the desired gene transferred thereto. Using the method of the present invention, even in animal species and lines for which in vitro transduction has been difficult to date, it is possible to obtain an individual harbouring germ cells, particularly spermatogonial stem cells, having a desired gene transferred thereto, at extremely high efficiency.Type: GrantFiled: May 25, 2005Date of Patent: May 18, 2010Assignee: Kyoto UniversityInventors: Takashi Shinohara, Mito Shinohara
-
Publication number: 20100122361Abstract: The present invention relates to the generation of transgenic animal cells and/or animals in which a large portion of a host animal's genome has been replaced with an equivalent syntenic portion of nucleic acid from the genome of a different organism.Type: ApplicationFiled: January 7, 2008Publication date: May 13, 2010Inventors: Andrew John Hammond Smith, Helen Anne Chapman Wallace, Douglas Roland Higgs
-
Publication number: 20100115642Abstract: The present invention relates to a method for providing a xenogenic immune system in an immunodeficient non-human mammal, to the obtained animal and to several uses of this animal, among other for producing xenogenic T cells.Type: ApplicationFiled: June 3, 2009Publication date: May 6, 2010Inventors: Kees Weijer, Nicolas Legrand
-
Publication number: 20100115640Abstract: Methods are disclosed in which the expression of a specific gene, or combinations of genes, is controlled spatially and temporally to develop intra- and interspecies chimeras. A transgenic EC/ES/P/iPS cell line is created which conditionally expresses a suicide or compromiser gene configured to compromise all cell lineages except that corresponding to a target tissue/organ. The EC/ES/P/iPS cell line is injected into donor embryos having a specific target gene deficiency or embryos genetically engineered to be complementary compromised in lineages corresponding to the target tissue/organ cell lineages of the EC/ES/P/iPS line. One or more stimuli is provided to the embryo to activate compromiser genes for ablation of non-target tissues/organs of the EC/ES/P/iPS line and target tissues/organs of the host embryo, resulting in a chimeric animal having target tissues/organs derived from the genotype of the transgenic cell line and all remaining tissues/organs derived from the donor embryo.Type: ApplicationFiled: March 7, 2008Publication date: May 6, 2010Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Chongbei Zhao, Andras Nagy, John K. Critser
-
Publication number: 20100115636Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA 2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.Type: ApplicationFiled: March 6, 2008Publication date: May 6, 2010Applicant: AARHUS UNIVERSITETInventors: Peter Michael Kragh, Lars Axel Bolund, Charlotte Brandt Sorensen, Thomas Juhl Corydon, Niels Gregersen, Peter Bross
-
Patent number: 7709696Abstract: A method of inducing transposition in a transgenic embryo, sperm and egg is described, comprising the steps of (a) generating a first adult transgenic organism comprising within its genome one or more copies of a transposon; (b) generating a second adult transgenic organism comprising within its genome one or more copies of a gene encoding a transposase cognate for the transposon and/or a sequence capable of regulating expression of the gene encoding the transposase; (c) crossing the first adult transgenic organism with the second transgenic adult organism to provide a progeny which comprises, in the genome of one or more of its cells, both (i) one or more copies of the transposon and (ii) a gene encoding a transposase cognate for the transposon, wherein the gene encoding the transposase is under the control of one or more inducible regulatory sequences which permit expression of the transposase, and (d) expressing the gene encoding the transposase in the embryo, sperm or egg to cause mobilization of the tranType: GrantFiled: July 9, 2004Date of Patent: May 4, 2010Assignees: Erasmus University Medical Center, Minos Biosystems LimitedInventors: Roger Craig, Charalambos Savakis, Frank Grosveld